U.S. Markets open in 2 hrs 20 mins
  • S&P Futures

    4,575.50
    -0.25 (-0.01%)
     
  • Dow Futures

    34,622.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    15,988.00
    -0.50 (-0.00%)
     
  • Russell 2000 Futures

    2,204.90
    -0.30 (-0.01%)
     
  • Crude Oil

    68.31
    +1.81 (+2.72%)
     
  • Gold

    1,772.70
    +10.00 (+0.57%)
     
  • Silver

    22.34
    +0.02 (+0.11%)
     
  • EUR/USD

    1.1311
    +0.0005 (+0.0452%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • Vix

    27.72
    -3.40 (-10.93%)
     
  • GBP/USD

    1.3262
    -0.0040 (-0.3010%)
     
  • USD/JPY

    113.3200
    +0.1110 (+0.0980%)
     
  • BTC-USD

    57,147.64
    +953.61 (+1.70%)
     
  • CMC Crypto 200

    1,459.43
    +20.55 (+1.43%)
     
  • FTSE 100

    7,150.05
    +20.84 (+0.29%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational highlights in a conference call on November 5, 2020 at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-877-317-6789 and international callers should dial 1-412-317-6789, approximately five minutes before the call.

  • All participants should ask to be connected to the Intellia Therapeutics conference call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on November 5, 2020 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investor Contact:
Lina Li
Associate Director, Investor Relations
+1 857-706-1612
lina.li@intelliatx.com

Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com